New report shows a coordinated approach is needed to ensure academic discoveries are not lost and can be taken forward with industry to develop new treatments

In a quiet laboratory at the University of Manchester, a team of scientists huddles around an intricate piece of technology designed to replicate human organ systems—an innovation aimed at reducing the costs and time associated with clinical trials. This advanced model may hold the key to curing diseases currently deemed untreatable, yet its potential could evaporate before it ever reaches the market. Despite the promise of cutting-edge research, academic discoveries often languish in obscurity, failing to transition into the pharmaceutical sphere where they could significantly change lives.

The Translational Readiness Gap

As unveiled in a landmark review published by the Association of the British Pharmaceutical Industry (ABPI) and the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), the UK possesses remarkable capabilities in developing human-relevant pre-clinical models. However, these models often lack what researchers term “translational readiness,” a crucial factor that determines whether innovation can be seamlessly adopted into commercial medicine development.

The review, titled From models to medicines: A landscape review of human-relevant pre-clinical model development in the UK, reveals that only about 10% of drug research and development programs successfully progress to the approval stage. Most failures stem from inadequate predictive methods for identifying effective treatments during pre-clinical stages. According to Dr. Sarah McIntosh, a leading researcher in pharmacology at Imperial College London, “This translational readiness gap represents an enormous lost opportunity not only for scientific advancement but also for patient care. We must align academic innovations with industry expectations to bridge this divide.”

Understanding Pre-Clinical Models

• Animal-Based Models: Traditional testing that often fails to accurately simulate human biology.
• Laboratory-Based Models: Innovative systems designed to mimic specific human organs.
• Computer Simulations: Advanced algorithms predicting drug behavior within human systems.

Pre-clinical models—whether grounded in animal studies, sophisticated laboratory constructs, or advanced computer simulations—are crucial for understanding human biology and initially testing potential treatments. When these models poorly simulate human responses, the ramifications extend beyond wasted funding; they delay treatment rollout and result in the continued reliance on outdated medications. The new review aptly identifies this lack of predictive capacity as a significant bottleneck in drug discovery.

Tackling the Challenges

The report introduces the Translational Readiness Framework to assess model viability and outlines essential criteria necessary to enhance the transition of academic discoveries into promising therapeutic options.

Key Factors for Increasing Readiness

• Materials: Utilization of the most suitable components for specific applications rather than defaulting to what is readily available.
• Technical Limitations: Development of multi-organ systems which accurately recreate how treatments behave in a human body must be prioritized.
• Infrastructure Gaps: Increased investment is essential to transform academic models into scientifically robust, validated systems for pharmaceutical use.

These critical factors are not mere suggestions; they are prerequisites for elevating the standard of pre-clinical models. Dr. Vicky Robinson, Chief Executive of the NC3Rs, emphasized the need for focused investment: “Our collaboration with the ABPI points to the immediate need for rigorous validation processes that ensure models can be fully translated into effective treatments.”

The Road Ahead: Collaborative Efforts

The review highlights substantial opportunities ahead, especially with the recent announcement of the 2025 Life Sciences Sector Plan. The establishment of a pre-clinical translational models hub promises to unite industry and academic scientists, facilitating the collaborative development of models for medicinal advancement. “This hub will foster an environment of shared knowledge and resources, allowing us to tackle challenges together,” noted Dr. Joanna Jenkinson, Director of Innovation and Research Policy at the ABPI.

Furthermore, the projected creation of a UK Centre for Validation of Alternative Methods aims to establish clear qualification pathways and standards, delivering the regulatory clarity necessary for the broader adoption of innovative models.

Professor Patrick Chinnery, Executive Chair of the Medical Research Council, conveyed optimism regarding these developments, stating, “The government and commercial funders recognize the critical need for high-quality human-relevant models. Collaborative efforts can and must overcome barriers to development.”

As researchers like those at the University of Manchester continue to innovate, the time is ripe for robust dialogue and increased collaboration between academic institutions and pharmaceutical companies. The efficacy of future treatments may hinge on a unified commitment to overcoming these translational challenges—ensuring no breakthrough is lost to the abyss of laboratory obscurity.

Source: www.abpi.org.uk